{"name": "Crucell",
 "permalink": "crucell",
 "crunchbase_url": "http://www.crunchbase.com/company/crucell",
 "homepage_url": "http://www.crucell.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 1993,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "biotech",
 "alias_list": "",
 "email_address": "info@crucell.com",
 "phone_number": "31(0)-71-519-91-00",
 "description": "Pharmaceutical Development",
 "created_at": "Mon Sep 28 23:33:09 UTC 2009",
 "updated_at": "Tue Feb 21 01:42:59 UTC 2012",
 "overview": "\u003Cp\u003ECrucell N.V. is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell\u0026#8217;s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       72],
      "assets/images/resized/0006/1057/61057v1-max-150x150.png"],
     [[233,
       113],
      "assets/images/resized/0006/1057/61057v1-max-250x250.png"],
     [[233,
       113],
      "assets/images/resized/0006/1057/61057v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Board memeber",
    "person":
     {"first_name": "Martijn",
      "last_name": "Kleijwegt",
      "permalink": "martijn-kleijwegt-3",
      "image":
       {"available_sizes":
         [[[109,
            150],
           "assets/images/resized/0027/5904/275904v1-max-150x150.jpg"],
          [[183,
            250],
           "assets/images/resized/0027/5904/275904v1-max-250x250.jpg"],
          [[230,
            314],
           "assets/images/resized/0027/5904/275904v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Member of Supervisory Board",
    "person":
     {"first_name": "George",
      "last_name": "R. Siber",
      "permalink": "george-r-siber",
      "image":
       {"available_sizes":
         [[[101,
            150],
           "assets/images/resized/0026/9137/269137v1-max-150x150.jpg"],
          [[169,
            250],
           "assets/images/resized/0026/9137/269137v1-max-250x250.jpg"],
          [[304,
            450],
           "assets/images/resized/0026/9137/269137v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Director Group Reporting and Financial Control",
    "person":
     {"first_name": "Paul",
      "last_name": "van Hagen",
      "permalink": "paul-van-hagen",
      "image":
       {"available_sizes":
         [[[109,
            150],
           "assets/images/resized/0027/5866/275866v1-max-150x150.jpg"],
          [[183,
            250],
           "assets/images/resized/0027/5866/275866v1-max-250x250.jpg"],
          [[230,
            314],
           "assets/images/resized/0027/5866/275866v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Senior Director Industrialization",
    "person":
     {"first_name": "Richard",
      "last_name": "H Holslag",
      "permalink": "richard-h-holslag",
      "image":
       {"available_sizes":
         [[[109,
            150],
           "assets/images/resized/0027/5864/275864v1-max-150x150.jpg"],
          [[183,
            250],
           "assets/images/resized/0027/5864/275864v1-max-250x250.jpg"],
          [[230,
            314],
           "assets/images/resized/0027/5864/275864v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Manager Group Reporting and Financial Control",
    "person":
     {"first_name": "Paul",
      "last_name": "van Hagen",
      "permalink": "paul-van-hagen",
      "image":
       {"available_sizes":
         [[[109,
            150],
           "assets/images/resized/0027/5866/275866v1-max-150x150.jpg"],
          [[183,
            250],
           "assets/images/resized/0027/5866/275866v1-max-250x250.jpg"],
          [[230,
            314],
           "assets/images/resized/0027/5866/275866v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$443M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.fiercebiotech.com/story/breaking-news-j-j-grabs-443m-stake-crucell-inks-flu-pact/2009-09-28?utm_medium=rss\u0026utm_source=rss\u0026cmp-id=OTC-RSS-FB0#ixzz0SRnF1h2S",
    "source_description": "J\u0026J grabs $443M stake in Crucell, inks flu pact",
    "raised_amount": 443000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 9,
    "funded_day": 28,
    "investments":
     [{"company":
        {"name": "Johnson \u0026 Johnson",
         "permalink": "johnson-johnson",
         "image":
          {"available_sizes":
            [[[150,
               31],
              "assets/images/resized/0005/9341/59341v1-max-150x150.jpg"],
             [[221,
               47],
              "assets/images/resized/0005/9341/59341v1-max-250x250.jpg"],
             [[221,
               47],
              "assets/images/resized/0005/9341/59341v1-max-450x450.jpg"]],
           "attribution": null}},
       "financial_org": null,
       "person": null}]}],
 "investments":
  [],
 "acquisition":
  {"price_amount": 2300000000.0,
   "price_currency_code": "USD",
   "term_code": "cash",
   "source_url": "http://www.fiercebiotech.com/story/crucell-eagerly-accepts-2-3b-buyout-offer-j-j/2010-09-17",
   "source_description": "Crucell eagerly accepts $2.3B buyout offer from J\u0026J ",
   "acquired_year": 2011,
   "acquired_month": 2,
   "acquired_day": 22,
   "acquiring_company":
    {"name": "Johnson \u0026 Johnson",
     "permalink": "johnson-johnson",
     "image":
      {"available_sizes":
        [[[150,
           31],
          "assets/images/resized/0005/9341/59341v1-max-150x150.jpg"],
         [[221,
           47],
          "assets/images/resized/0005/9341/59341v1-max-250x250.jpg"],
         [[221,
           47],
          "assets/images/resized/0005/9341/59341v1-max-450x450.jpg"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Archimedesweg 4-6",
    "address2": "",
    "zip_code": "",
    "city": "Leiden",
    "state_code": null,
    "country_code": "NLD",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": 2011,
   "pub_month": 3,
   "pub_day": 29,
   "stock_symbol": "PINK:CRXLY"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        123],
       "assets/images/resized/0006/2910/62910v1-max-150x150.jpg"],
      [[250,
        205],
       "assets/images/resized/0006/2910/62910v1-max-250x250.jpg"],
      [[450,
        370],
       "assets/images/resized/0006/2910/62910v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}